MedTrace Logo

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2011-08-23

No results posted yet for this study

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

Conditions

Interventions

DRUG

ABT-089

10 mg - capsules once daily for 12 weeks

DRUG

ABT-089

5 mg - capsules once daily for 12 weeks

DRUG

ABT-089

15 mg - capsules once daily for 12 weeks

DRUG

ABT-089

20 mg - capsules once daily for 12 weeks

DRUG

ABT-089

30 mg - capsules once daily for 12 weeks

DRUG

ABT-089

35 mg - capsules once daily for 12 weeks

DRUG

placebo

placebo - capsules once daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Robert Lenz, MD, PhD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555204 on ClinicalTrials.gov